Home » Dynavax’s Hep B Vaccine Meets Primary Endpoints
Dynavax’s Hep B Vaccine Meets Primary Endpoints
Dynavax by March will refile a BLA for its hepatitis B vaccine Heplisav-B by the end of this quarter after seeing success in a Phase 3 trial.
The investigational drug demonstrated efficacy in a head-to-head trial versus GlaxoSmithKline’s Engerix-B vaccine in adults 18 to 70. Heplisav-B offered greater seroprotection against the virus across the board, particularly in diabetic patients considered to be at greater risk.
Dynavax originally submitted its Heplisav-B BLA in 2012, and it received a February 2013 FDA complete response letter. The agency wanted more safety data, given autoimmune risks with novel adjuvants, and it asked for additional process validation data on manufacturing controls.
Upcoming Events
-
21Oct